A case of traumatic cerebral oedema is reported in which the infusion of small volumes of stable plasma protein solution (SPPS) resulted in acute and massive increases in intracranial pressure. The batch of SPPS responsible was found to have high levels of prekallikrein activator which is thought to be the cause of the systemic hypotension previously described with plasma proteins solutions. A second batch of SPPS with low levels of prekallikrein activator generated much smaller increases in intracranial pressure. The mechanism of this phenomenon is discussed and a recommendation made for the cautious use of SPPS when intracranial hypertension is present or suspected.
contains 5070 protein, largely as albumin and is widely used as a volume expander and in hypoproteinaemic states. The hypotensive effects of SPPS have been well documented with a number of studies attributing these reactions to peripheral vasodilatation. 1 - 4 The reactions have been most marked with rapid infusion rates and associated with cardiopulmonary bypass. Although some batches of SPPS contain significant quantities of a bradykinin-like substance, the presence of excessive quantities of prekallikrein activator (PKA) is thought to be the most likely cause of the reactions. PKA is frequently present in plasma protein solutions, but rarely in human concentrated albumin.
We now report the occurrence of acute intracranial hypertension following the administration of SPPS to a child with a severe head injury. This complication of SPPS has not previously been reported, but it is reasonable to assume that patients with severe head injuries who lie on the steep part of the intracranial compliance curve, may incur acute rises in intracranial pressure (ICP) following administration of any cerebral vasodilator.
CASE REPORT
A previously healthy eight-year-old girl weighing 25 kg was involved in a motor vehicle accident and suffered a severe head injury and fractures to her left olecranon and right femur. After admission to the Intensive Care Unit, she was transferred to theatre where a right frontal burr hole was made and a catheter inserted into the lateral ventricle for intracranial pressure monitoring. Pressure was monitored via a Bentley Trantec strain gauge transducer connected to Electronics for Medicine monitoring equipment. A permanent record was made using a Hewlett-Packard slow paper recorder. Arterial and central venous pressures were monitored simultaneously.
Anaesthesia and Intensive Care, Vol, Vl/f, ,\'0. 4, November, 1980 A moderate elevation of intracranial pressure (20-30 mmHg) was found on commencement of monitoring. Standard therapy consisting of head-up tilt, fluid restriction, steroids and hyperventilation was instituted to reduce brain swelling and intracranial blood volume.
Clinical examination revealed arterial hypotension, poor peripheral perfusion, a central venous pressure of zero and poor urine output. This was interpreted as hypovolaemia and an infusion of SPPS (Batch 1637 -lR) was commenced. There was a rapid rise in intracranial pressure (ICP) from 21 mmHg to 51 mmHg (Figure 1 ). The infusion was terminated after only 40 ml had been given and the intracranial pressure returned to preinfusion levels within a few minutes. 20 ml aliquots of the same solution were introduced on three subsequent occasions, and on each a significant rise in intracranial pressure occurred immediately (Figures 1 and 2) . These rises are set out in Table 1 . Only on the last occasion was any significant arterial hypotension noted when mean arterial pressure fell from 71 mmHg to 63 mmHg. There was no arterial hypertension and no change in central venous pressure with any of these infusions. A solution of gelatin polypeptide (Haemaccel) was substituted to provide volume expansion and no rise in intracranial pressure occurred during this administration. The child was then exposed to a second batch of SPPS (Batch 1924 -1) and after only 20 ml the ICP rose from 25 to 32 mmHg and the infusion was stopped. The bradykinin-like activity was measured by bioassay using the rabbit ear vein and is expressed in bradykinin equivalents. Bottle number 1 contained approximately 2.7 ng/ml and bottle number 2 contained 2.0 ng/m!.
DISCUSSION
The adverse reactions due to SPPS resemble those caused by intravenous infusion of bradykinin. Although some batches of the plasma protein solutions contain significant quantities of a kinin-like substance, which probably contributes to the reaction, the presence of excessive quantities of PKA is thought to be the likely cause of the reactions. 5 The proposed mechanism for induction of hypotension by PKA is illustrated in Figure 3 . Electrophoresis of both batches of SPPS demonstrated that they contained largely albumin and small amounts of a-I, a-2, and ~-globulin. Samples from both batches of SPPS were returned to the Commonwealth Serum Laboratories for examination. The results of these investigations are included in Table 1 hypotension except during cardiopulmonary bypass or in the presence of large right to left shunts. PKA however has a longer half life and thus recirculates several times allowing bradykinin release on the arterial side of the circulation.
Patients with severe head injuries usually have gross disruption of the blood-brain barrier causing mar ked cerebral swelling. These patients have intracranial pressures which lie on the steep part of the intracranial compliance curve, and any further rises in intracranial volume will produce large and rapid increases in ICP (Figure 4 ). In this particular case it seems likely that the repeated increases in ICP were due to an increase in cerebral blood volume caused by cerebral vasodilatation. A fall in mean arterial pressure occurred with only one infusion of SPPS suggesting that there was little peripheral vasodilatation, possibly due to the small volumes infused. Minimal cerebral vasodilatation however, may produce large rises in ICP in a non-compliant situation.
The usual response to an increase in ICP is a rise in systemic blood pressure. As there was no increase in blood pressure, it is possible that the Anaesthesia and Intensive Care, Vol. VIII, No. 4, November, 1980 presence of circulating kinins had modified the hypertensive response whilst not producing significant hypotension. The acute increases in ICP without concomitant rises in systemic blood pressure imply a reduction in cerebral perfusion pressure and, when autoregulation is impaired, and the risk of additional cerebral damage. These findings highlight the value of continuous ICP monitoring in patients with cerebral oedema.
Two different batches of SPPS were used. Bottle number 1 contained a very high level of PKA activity (35.6070) and caused massive increases in intracranial pressure. The Commonwealth Serum Laboratories now monitor PKA activity and accept 20% activity of the known reference sample as the cutoff point; only batches with less than 20% activity are now released. The first bottle used in fact had been released prior to the routine monitoring of PKA activity. Bottle number 2 contained a much lower level of PKA activity (3.7%) and caused a somewhat smaller although significant rise in ICP. Both batches contained minute and similar bradykinin-like activity. Similar volumes of a gelatin polypeptide solution (Haemaccel) that does not possess vasoactivity, produced no changes in ICP.
It seems likely that SPPS with PKA activity less than 20% and hence considered safe from the aspect of systemic hypotension, may have deleterious effects on intracranial pressure in the presence of cerebral oedema.
SPPS is also widely used as a volume expander in the care of critically ill neonates. The risk of cerebral haemorrhage associated with hypertonic sodium bicarbonate therapy is well established. This is attributed to sudden changes in cerebral blood flow and capillary dilatation. The sudden changes in cerebral blood flow and volume that may accompany the use of SPPS should be borne in mind when considering possible associations with intracranial haemorrhage in neonates.
It is recommended that SPPS be used with great caution if raised intracranial pressure is either present or suspected and preferably given in conjunction with continuous monitoring of ICP. Thought should be given to the use of other volume expanders devoid of these vasoactive properties.
